In a strategic move to enhance its global technological capabilities, U.S.-based biopharmaceutical giant Amgen has announced an initial investment of $200 million in a new technology and innovation center located in Hyderabad, India. This announcement was made by CEO Robert Bradway during the inauguration ceremony on February 24, 2025.
Focus on Artificial Intelligence and Data Science
The Hyderabad center is poised to become a pivotal hub for Amgen’s digital transformation efforts. The facility will concentrate on integrating artificial intelligence (AI) and data science into the company’s drug development processes, aiming to accelerate the discovery and development of new medicines. This initiative underscores Amgen’s commitment to leveraging cutting-edge technology to address complex medical challenges.
Expansion Plans and Employment Opportunities
Amgen’s investment is not limited to infrastructure alone. The company has outlined plans to expand its workforce in Hyderabad significantly. Currently, the center employs approximately 300 professionals, with projections to increase this number to around 2,000 by the end of the year. This rapid expansion highlights the region’s rich talent pool and Amgen’s dedication to fostering innovation through human capital.
Strengthening U.S.-India Pharmaceutical Collaboration
Amgen’s decision to establish a significant presence in India aligns with the broader trend of multinational pharmaceutical companies recognizing the strategic importance of the Indian market. India, often referred to as the “pharmacy of the world,” offers a unique combination of skilled professionals and a conducive environment for pharmaceutical research and development. This investment also coincides with ongoing discussions between the United States and India aimed at resolving trade disputes and enhancing collaboration in critical and emerging technologies.
Hyderabad: A Growing Hub for Biotechnology
The choice of Hyderabad for Amgen’s new center is a testament to the city’s burgeoning status as a biotechnology and pharmaceutical hub. The city is set to host the BioAsia conference, attracting industry leaders from global pharmaceutical giants such as Eli Lilly and Novartis, as well as prominent Indian pharmaceutical companies. This convergence of industry experts underscores Hyderabad’s growing significance in the global pharmaceutical landscape.
Future Outlook
Amgen’s $200 million investment marks the beginning of a long-term commitment to expanding its operations in India. With plans for additional significant investments in the coming years, the Hyderabad technology center is poised to play a crucial role in Amgen’s global strategy to harness innovation, talent, and technology in the pursuit of advancing healthcare solutions worldwide.
